Chapter 11

Showing 735 articles
Business

Veeva Systems: A Buying Opportunity or Overvalued Tech Play? Analysts Weigh In

Veeva Systems' stock has faced recent pressure, declining over 11% in the past year. A deep dive into its valuation reveals a stark contrast: a discounted cash flow model suggests significant upside, while its premium P/E ratio tells a more cautious tale. We examine the numbers and what they mean for investors eyeing the life sciences cloud leader.

Sanofi Halts mRNA Flu Vaccine Trial Amid Surging U.S. Influenza Season

French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.